全球人冠状病毒抗体领域研发现状与发展趋势

doi:10.13523/j.cb.2002106

中国生物工程杂志

2020, Vol. 40

Issue (1-2): 65-70 DOI: 10.13523/j.cb.2002106

冠状病毒药物研发与技术情报专辑

全球人冠状病毒抗体领域研发现状与发展趋势

李东巧,吕璐成,杨艳萍(

)

中国科学院文献情报中心北京 100190

The Research Status and Development Trend of Global Human Coronavirus Antibody Field

LI Dong-qiao,LV Lu-cheng,YANG Yan-ping(

)

National Science Library, Chinese Academy of Sciences, Beijing 100190, China

全文: PDF(789 KB) HTML

摘要：

抗体在疾病的诊断、治疗和预防方面发挥着重要作用。随着2019新型冠状病毒(SARS-CoV-2)感染引起的肺炎不断传播,如何研发针对该病毒的抗体迫在眉睫。基于IncoPat数据库的专利信息和Cortellis数据库的药物信息,采用定量分析与定性调研相结合的方法,从申请趋势、技术分布、国家/地区分布、机构分布以及市场现状等维度对人冠状病毒抗体领域的专利进行态势分析。结果表明美国是专利技术拥有量最大的国家,中国是专利保护的重点国家。中国科学院等3家国内机构进入全球前十位。人冠状病毒抗体产品研发主要以SARS和MERS为主,部分MERS抗体已进入临床阶段。研究结果为2019冠状病毒病(COVID-19)的相关抗体研发提供数据参考与决策支撑。

关键词： 人冠状病毒; 抗体; 专利布局; 发展趋势

Abstract:

Antibodies play an important role in the diagnosis, treatment and prevention of diseases. With the continuous spread of pneumonia caused by the infection of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2), it is urgent to research antibodies against the virus. The patent information was downloaded from the IncoPat database and the drug information was downloaded from the Cortellis database. Through the combination of quantitative analysis and qualitative research, the patent situation analysis in the field of human coronavirus could be obtained from various dimensions, including application trends, technology distribution, country or region distribution, organization distribution and market status. The results showed that the United States was the country with the largest amount of patent technology, and China was the main country of patent protection. Three Chinese organizations, including the Chinese Academy of Sciences, entered the list of the global top ten organizations. The research on human coronavirus antibody products was mainly focused on SARS and MERS. In addition, some MERS antibodies entered the clinical stage. The results provide data reference and decision support for the research and development of Corona Virus Disease 2019(COVID-19).

Key words: Human coronavirus Antibody Patent layout Development trend

收稿日期: 2020-02-11 出版日期: 2020-03-27

ZTFLH:

Q819

通讯作者: 杨艳萍 E-mail: yangyp@mail.las.ac.cn

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李东巧
	吕璐成
	杨艳萍

引用本文:

李东巧,吕璐成,杨艳萍. 全球人冠状病毒抗体领域研发现状与发展趋势[J]. 中国生物工程杂志, 2020, 40(1-2): 65-70.

LI Dong-qiao,LV Lu-cheng,YANG Yan-ping. The Research Status and Development Trend of Global Human Coronavirus Antibody Field. China Biotechnology, 2020, 40(1-2): 65-70.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2002106 或 https://manu60.magtech.com.cn/biotech/CN/Y2020/V40/I1-2/65

图1 全球人冠状病毒抗体专利数量年度趋势

图2 人冠状病毒抗体专利主要分布

表1 全球人冠状病毒抗体专利主要技术来源国家分析

表2 全球冠状病毒抗体专利主要技术受理国家分析

表3 全球人冠状病毒抗体专利申请全球TOP 10机构和中国TOP 6机构

图3 全球人冠状病毒诊断性抗体专利申请全球TOP 6机构

图4 全球人冠状病毒治疗性抗体专利申请全球TOP 5机构

表4 全球人冠状病毒抗体四方专利

表5 全球人冠状病毒抗体领域药物研发阶段分析

[1]	李东巧, 陈芳, Cynthia Liu , 等. 全球抗体药物研发态势分析. 中国生物工程杂志, 2019,39(5):11-21.
	Li D Q, Chen F, Liu C , et al. Analysis of global antibody drug development trends. China Biotechnology, 2019,39(5):11-21.
[2]	Sui J H, Li W H, Murakami A , et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. PNAS, 2004,101(8):2536-2541.
[3]	Cleri D J, Ricketti A J, Vernaleo J R . Severe acute respiratory syndrome (SARS). Infectious Disease Clinics of North America, 2010,24(1):175.
[4]	Zhu Z Y, Chakraborti S, He Y , et al. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. PNAS, 2007,104(29):12123-12128.
[5]	Ohnuma K, Haagmans B L, Hatano R , et al. Inhibition of Middle East Respiratory Syndrome coronavirus infection by anti-CD26 monoclonal antibody. Journal of Virology, 2013,87(24):13892-13899.
[6]	Ying T L, Du L Y, Ju T W , et al. Exceptionally potent neutralization of Middle East Respiratory Syndrome coronavirus by human monoclonal antibodies. Journal of Virology, 2014,88(14):7796-7805.
[7]	Qiu T Y, Mao T T, Wang Y , et al. Identification of potential cross-protective epitope between 2019-nCoV and SARS virus. Journal of Genetics and Genomics, 2020, In Press Journal Pre-proof.

[1]	陈修月,周文锋,何庆,苏冰,邹亚文. 噬菌体Qβ病毒样颗粒的制备、纯化及鉴定[J]. 中国生物工程杂志, 2021, 41(7): 42-49.
[2]	陈文洁,苗先锋. 抗体偶联药物国内研发现状及企业布局分析[J]. 中国生物工程杂志, 2021, 41(6): 105-110.
[3]	许叶春,柳红,李剑峰,沈敬山,蒋华良. 抗新冠肺炎药物研究进展[J]. 中国生物工程杂志, 2021, 41(6): 111-118.
[4]	史瑞,严景华. 抗新型冠状病毒单克隆中和抗体药物研发进展^*[J]. 中国生物工程杂志, 2021, 41(6): 129-135.
[5]	原博,王杰文,康广博,黄鹤. 双特异性纳米抗体的研究进展及其应用 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 78-88.
[6]	毛开云,李荣,李丹丹,赵若春,范月蕾,江洪波. 全球双特异性抗体药物研发格局分析^*[J]. 中国生物工程杂志, 2021, 41(11): 110-118.
[7]	张赛,向乐,李林海,李辉军,王刚,钱纯亘. 新型冠状病毒(2019-nCoV)IgM /IgG抗体检测试剂的研制及性能评价[J]. 中国生物工程杂志, 2020, 40(8): 1-9.
[8]	赵妍淑,张金华,宋浩. 工程原核生物和酵母菌中生产单克隆抗体和抗体片段研究进展 ^*[J]. 中国生物工程杂志, 2020, 40(8): 74-83.
[9]	蔺士新,刘东晨,雷云,熊盛,谢秋玲. TNF-α纳米抗体的筛选、表达及特异性检测 ^*[J]. 中国生物工程杂志, 2020, 40(7): 15-21.
[10]	杨笑莹,李梦,赵威,唐敏,张志谦. 抗α2δ1/CD3双特异性抗体的制备和功能的初步研究 ^*[J]. 中国生物工程杂志, 2020, 40(7): 9-14.
[11]	武瑞君,李治非,张鑫,濮润,敖翼,孙燕荣. 新冠病毒抗体药物研发进展及展望分析[J]. 中国生物工程杂志, 2020, 40(5): 1-6.
[12]	王猛,宋慧茹,程雨洁,王毅,杨波,胡征. 以核糖体蛋白L7/L12为分子标志物精准检测肺炎链球菌的研究 ^*[J]. 中国生物工程杂志, 2020, 40(4): 34-41.
[13]	杨丽,石晓宇,李文蕾,李剑,徐寒梅. 构建噬菌体展示抗体库过程中电穿孔法的条件优化[J]. 中国生物工程杂志, 2020, 40(4): 42-48.
[14]	李彤彤,宋彩玲,杨凯越,王文静,陈慧宇,刘明. 抗犬细小病毒VP2蛋白单链抗体的制备与中和活性研究 ^*[J]. 中国生物工程杂志, 2020, 40(4): 10-16.
[15]	陈秋利,杨丽超,李辉,温莎,李刚,何敏. 人Nek2蛋白原核表达纯化及其多克隆抗体制备 ^*[J]. 中国生物工程杂志, 2020, 40(3): 31-37.

Viewed

Full text

Abstract

Cited

Shared

Discussed